Fate Therapeutics, Inc. Stock Analysis & AI Score
Fate Therapeutics, Inc. (FATE) has an ST Score of 53.5 (B-), driven by its Sentiment (A+) and held back by its Growth (D+). Analysts rate it Buy with a $5.63 price target (+141.6% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Fate Therapeutics, Inc. (FATE) has an ST Score of 53.5 (B-), driven by its Sentiment (A+) and held back by its Growth (D+). Analysts rate it Buy with a $5.63 price target (+141.6% upside).
- Strongest
- SentimentA+
- Weakest
- GrowthD+
All factor grades
- SentimentA+
- ForecastA
- MomentumB+
- ValuationC+
- ProfitabilityC
- Financial StrengthD+
- GrowthD+
- Piotroski3/9
Contact
FATE stock: frequently asked questions
What is FATE's ST Score?
Fate Therapeutics, Inc. (FATE) has an ST Score of 53.5 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is FATE a buy, hold, or sell?
Analysts rate FATE a Buy, with a price target of $5.63 (+141.6% vs the current price). Our ST Score grades it B- (53.5/100). The ST Score is a data-driven signal, not a recommendation.
What are FATE's factor grades?
Valuation C+, Profitability C, Financial Strength D+, Momentum B+, Growth D+, Forecast A, Sentiment A+.
What is FATE's valuation grade?
Fate Therapeutics, Inc. (FATE) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is FATE's growth grade?
Fate Therapeutics, Inc. (FATE) earns a growth grade of D+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is FATE's profitability grade?
Fate Therapeutics, Inc. (FATE) earns a profitability grade of C, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is FATE's financial strength grade?
Fate Therapeutics, Inc. (FATE) earns a financial strength grade of D+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for FATE?
The average analyst price target for Fate Therapeutics, Inc. (FATE) is $5.63 from 31 analysts, which is +141.6% versus the recent price of $2.33.
What is FATE's Piotroski score?
Fate Therapeutics, Inc. (FATE) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.